Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: Twelve-month results from the BIOLUX P-I randomized trial

Journal of Endovascular Therapy

Volumn 22, Issue 1, 2015, Pages 14-21

  Scheinert, Dierk ^a   Schulte, Karl Ludwig ^b   Zeller, Thomas ^c   Lammer, Johannes ^d   Tepe, Gunnar ^e  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b Königin Elisabeth Herzberge Hospital   (Germany)

^c UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Rosenheim Hospital   (Germany)

Author keywords

Balloon angioplasty; BTHC; Drug eluting balloon; Drug releasing balloon; Drugcoated balloon; Femoropopliteal lesions; Occlusion; Paclitaxel coated balloon; Peripheral artery disease; Popliteal artery; Restenosis; Stenosis; Superficial femoral artery

Indexed keywords

BUTYRYL TRI NHEXYL CITRATE; EXCIPIENT; PACLITAXEL; UNCLASSIFIED DRUG; BIOMATERIAL; BUTYRIC ACID DERIVATIVE; BUTYRYL-N-TRIHEXYLCITRATE; CARDIOVASCULAR AGENT;

AGED; ANKLE BRACHIAL INDEX; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEVICE SAFETY; DISEASE CLASSIFICATION; DRUG COATING; FEMALE; FEMOROPOPLITEAL LESION; FOLLOW UP; HEART DEATH; HUMAN; IN-STENT RESTENOSIS; INTENTION TO TREAT ANALYSIS; LEG AMPUTATION; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PACLITAXEL COATED BALLOON; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; VASCULAR ACCESS; AUSTRIA; CLINICAL TRIAL; FEMORAL ARTERY; GERMANY; LIMB SALVAGE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; RADIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; ANKLE BRACHIAL INDEX; AUSTRIA; BUTYRATES; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; EXCIPIENTS; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; GERMANY; HUMANS; LIMB SALVAGE; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84938574636     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602814564383     Document Type: Article

References (20)

1. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 2013; 382: 1329-1340.
2. Rocha-Singh KJ, Jaff MR, Crabtree TR, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007; 69: 910-919.
3. Zeller T, Schmitmeier S, Tepe G, et al. Drug-coated balloons in the lower limb. J Cardiovasc Surg (Torino). 2011; 52: 235-243.
4. Joner M, Byrne RA, Lapointe JM, et al. Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. Thromb Haemost. 2011; 105: 864-872.
5. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008; 358: 689-699.
6. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: Paclitaxel-coated versus uncoated balloon: Femoral paclitaxel randomized pilot trial. Circulation. 2008; 118: 1358-1365.
7. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: Evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012; 5: 831-840.
8. Hehrlein C, Dietz U, Kubica J, et al. Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER) trial. Cardiovasc Revasc Med. 2012; 13: 260-264.
9. Toelg R, Merkely B, Erglis A, et al. Coronary artery treatment with paclitaxel coated balloon using a BTHC excipient: Clinical results of the international real world DELUX registry. EuroIntervention. 2014; 10: 591-599.
10. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version. J Vasc Surg. 1997; 26: 517-538.
11. Erratum: J Vasc Surg. 2001; 33: 805.
12. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) trial for femoropopliteal revascularization: First-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014; 7: 10-19.
13. Joner M, Radke PW, Byrne RA, et al. Preclinical evaluation of a novel drug-eluting balloon in an animal model of in-stent stenosis. J Biomater Appl. 2013; 27: 717-726.
14. European Stroke Organization, Tendera M, Aboyans V, et al; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32: 2851-2906.
15. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007; 33(suppl 1): S1-S75.
16. Diehm N, Baumgartner I, Jaff M, et al. A call for uniform reporting standards in studies assessing endovascular treatment for chronic ischaemia of lower limb arteries. Eur Heart J. 2007; 28: 798-805.
17. Micari A, Cioppa A, Vadalà G, et al. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: Evidence from a multicenter registry. JACC Cardiovasc Interv. 2013; 6: 282-289.
18. Micari A, Cioppa A, Vadalà G, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv. 2012; 5: 331-338.
19. Tepe G, Zeller T, Schnorr B, et al. High-grade, nonflow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: An additional analysis from the THUNDER study. J Endovasc Ther. 2013; 20: 792-800.
20. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: Twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011; 4: 495-504.